Jeffrey W. Albers Sells 15,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the completion of the transaction, the director now owns 157,557 shares of the company’s stock, valued at $14,143,891.89. This trade represents a 8.69 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Blueprint Medicines Trading Up 1.4 %

NASDAQ:BPMC opened at $90.14 on Friday. The business’s 50-day simple moving average is $92.48 and its 200-day simple moving average is $97.13. Blueprint Medicines Co. has a fifty-two week low of $72.24 and a fifty-two week high of $121.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The stock has a market capitalization of $5.73 billion, a PE ratio of -42.72 and a beta of 0.59.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. During the same quarter in the prior year, the company earned ($2.20) earnings per share. The business’s quarterly revenue was up 126.5% compared to the same quarter last year. Sell-side analysts expect that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Blueprint Medicines

Large investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC bought a new stake in shares of Blueprint Medicines in the second quarter valued at about $1,060,000. Federated Hermes Inc. lifted its stake in Blueprint Medicines by 27.8% in the 2nd quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock valued at $6,721,000 after acquiring an additional 13,579 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Blueprint Medicines by 48.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock worth $23,332,000 after acquiring an additional 82,693 shares during the last quarter. Nicholas Investment Partners LP acquired a new position in Blueprint Medicines during the 2nd quarter worth approximately $4,377,000. Finally, Entropy Technologies LP bought a new position in shares of Blueprint Medicines during the 3rd quarter worth approximately $999,000.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BPMC shares. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Wells Fargo & Company dropped their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a research note on Monday, December 9th. UBS Group assumed coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Blueprint Medicines currently has an average rating of “Moderate Buy” and an average target price of $122.11.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.